American International Group, Inc. Janux Therapeutics, Inc. Transaction History

American International Group, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$7.93 - $49.75 $570 - $3,582	-72 Reduced 0.84%	8,524 $320,000
Q4 2023 Feb 13, 2024	SELL	$5.85 - $11.7 $204 - $409	-35 Reduced 0.41%	8,596 $92,000
Q3 2023 Nov 13, 2023	BUY	$9.56 - $14.0 $2,934 - $4,298	307 Added 3.69%	8,631 $87,000
Q2 2023 Aug 04, 2023	BUY	$11.08 - $15.92 $465 - $668	42 Added 0.51%	8,324 $98,000
Q1 2023 May 12, 2023	BUY	$11.25 - $22.21 $1,845 - $3,642	164 Added 2.02%	8,282 $100,000
Q4 2022 Feb 10, 2023	SELL	$11.1 - $18.26 $321 - $529	-29 Reduced 0.36%	8,118 $106,000
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $1,244 - $1,936	115 Added 1.43%	8,147 $110,000
Q2 2022 Aug 12, 2022	SELL	$9.52 - $15.65 $7,435 - $12,222	-781 Reduced 8.86%	8,032 $98,000
Q1 2022 May 13, 2022	BUY	$13.24 - $20.24 $23,593 - $36,067	1,782 Added 25.34%	8,813 $126,000
Q4 2021 Feb 11, 2022	SELL	$15.44 - $27.32 $3,257 - $5,764	-211 Reduced 2.91%	7,031 $139,000
Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $149,909 - $251,224	7,242 New	7,242 $157,000

160

37.2M

70.4K

101K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.